Treatment of psoriasis vulgaris with a recombinant human tumor necrosis factor receptor:Fc fusion protein:a multicentre,randomized,double blind trial
- VernacularTitle:重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白治疗寻常性银屑病多中心、随机、双盲试验
- Author:
Qiong HUANG
;
Qin-Ping YANG
;
Xu FANG
;
Ling HAN
;
Zhi-Zhong ZHENG
;
Wen-Wen FU
;
Jian-Fang SUN
;
Yi-qun JIANG
;
Jun GU
;
Chun-fang GUO
;
Ai-e Xu
;
Jun-fan CHEN
;
Bing-hua SU
;
Qing-bo HE
- Publication Type:Journal Article
- Keywords:
Psoriasis;
Controlled clinical trials;
Methotrexate;
rhTNFR:Fc
- From:
Chinese Journal of Dermatology
2003;0(11):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the efficacy and tolerability of a recombinant human tumor necrosis factor:Fc fusion protein (rhTNFR:Fc,with a trade name of Yisaipu) in the treatment of moderate to severe psoriasis vulgaris.Methods A multicentre,randomized,double blind,and parallel-controlled trial was performed.One hundred and forty-four patients with moderate to severe psoriasis vulgaris from four centres were randomly assigned and treated with either once-weekly subcutaneous injection of rhTNFR:Fc (50 mg) or oral methotrexate (MTX)(7.5 mg) for 12 weeks.Patients were followed up at 2,4,8,12 weeks after the treatment.Results One hundred and twenty-four patients finished the 12-week course of treat- ment.At 12 weeks after the treatment,a 50%,75%,90% improvement in psoriasis area and severity index (PASI) was achieved by 86.11%,76.39%,52.78% respectively of rhTNFR:Fc-treated patients,and by 63.89%,44.44%,22.22% respectively in MTX-treated patients,and all the three improvement rates were of significant difference between the two groups of patients (all P0.05).Conclusion Compared with MTX,rhTNFR:Fc acts more quickly with a higher cure rate and less toxic reactions in the treatment of psoriasis vulgaris.
